Oncology and SVB Leerink

Selected news for the healthcare topic - Oncology, and the capital firm - SVB Leerink. We have 1,190 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/11/2022 Q2 2022 EPS Estimates for Kura Oncology, Inc. Lifted by Analyst (NASDAQ:KURA) Daily Political Q2 2022 EPS Estimates for Kura Oncology, Inc. Lifted by Analyst (NASDAQ:KURA) Posted by Latisha Jones on May 10th, 2022 Share on StocktwitsKura Oncology, Inc. ( NASDAQ:KURA ‚Ai Get Rating ) ‚Ai Research analysts at SVB Leerink increased their Q2 2022 earnings per share (EPS) estimates for Kura Oncology in a report issued on Wednesday, May 4th. SVB Leerink analyst J. Chang now anticipates that the company will post ...
5/6/2022 Kura Oncology (NASDAQ:KURA) Downgraded by Zacks Investment Research to Sell The Markets Daily Zacks Investment Research downgraded shares of Kura Oncology ( NASDAQ:KURA ‚Ai Get Rating ) from a hold rating to a sell rating in a research note issued to investors on Thursday, Zacks.com reports.According to Zacks ... outperform rating in a research note on Friday, February 25th. SVB Leerink decreased their price target on Kura Oncology from $41.00 to $28.00 and set an outperform rating on the stock in a research note ...
4/30/2022 Kura Oncology (NASDAQ:KURA) Downgraded by Zacks Investment Research to Sell - Stock Observer Zacks Investment Research downgraded shares of Kura Oncology ( NASDAQ:KURA ‚Ai Get Rating ) from a hold rating to a sell rating in a report published on Friday morning, Zacks.com reports.According to Zacks, ‚AuKura Oncology ... buy rating and a $35.00 price target on the stock. SVB Leerink reduced their price target on shares of Kura Oncology from $41.00 to $28.00 and set an outperform rating on the stock in a ...
4/19/2022 Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters‚Äô Option to Purchase Additional Shares ... April 18, 2022 (GLOBE NEWSWIRE) ‚Ai Affimed N.V. (Nasdaq: AFMD) (‚AuAffimed‚Au or the ‚AuCompany‚Au), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced ... the offering payable by Affimed, to $103.5 million.Jefferies LLC, SVB Leerink, Truist Securities, Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers and Berenberg Capital Markets LLC is acting as ...
4/11/2022 Zacks Investment Research Lowers Century Therapeutics (NASDAQ:IPSC) to Sell Daily Political Zacks Investment Research cut shares of Century Therapeutics ( NASDAQ:IPSC ‚Ai Get Rating ) from a hold rating to a sell rating in a research report released on Friday morning, Zacks.com reports. According to Zacks, ‚AuCentury Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA. ‚AuSeparately, SVB Leerink reiterated a buy rating ...
4/7/2022 Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up After Insider Buying Activity The Markets Daily Cullinan Oncology, Inc. ( NASDAQ:CGEM ‚Ai Get Rating )‚Aos stock price gapped up before the market opened on Wednesday after an insider bought additional shares in the company. The stock had previously closed at $12.14 ... rating in a research note on Tuesday, March 22nd. Finally, SVB Leerink restated an ‚Auoutperform‚Au rating on shares of Cullinan Oncology in a research note on Tuesday, February 8th.Cullinan Oncology ( NASDAQ:CGEM ‚Ai ...
4/7/2022 Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up on Insider Buying Activity - Stock Observer Cullinan Oncology, Inc. ( NASDAQ:CGEM ‚Ai Get Rating ) gapped up prior to trading on Wednesday after an insider bought additional shares in the company. The stock had previously closed at $12.14, but opened at $12.76 ... the company in a research report on Friday, March 18th. SVB Leerink reiterated an ‚Auoutperform‚Au rating on shares of Cullinan Oncology in a research report on Tuesday, February 8th. Finally, Zacks Investment Research lowered ...
4/6/2022 Bolt Biotherapeutics (NASDAQ:BOLT) Upgraded to ‚ÄúBuy‚Äù by Zacks Investment Research ... upside of 17.75% from the company‚Aos current price.According to Zacks, ‚AuBolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company ... Au rating in a research report on Thursday, January 6th. SVB Leerink reaffirmed a ‚Aubuy‚Au rating on shares of Bolt Biotherapeutics in a research report on Thursday, December 9th. Finally, Jonestrading reiterated a ‚Aubuy ...
3/30/2022 Calithera Biosciences, Inc. Prices $10.0 Million Globe Newswire SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 18,518,519 shares ... close on April 1, 2022, subject to customary closing conditions.SVB Leerink and H.C. Wainwright & Co. are acting as joint book-running managers for the offering.A shelf registration statement relating to the offered securities ...
3/27/2022 HC Wainwright Reaffirms “Buy” Rating for Innate Pharma (NASDAQ:IPHA) ... Investment Research cut Innate Pharma from a buy rating to a hold rating in a report on Tuesday, February 15th. SVB Leerink reiterated a buy rating on shares of Innate Pharma in a research report ... discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the ...
3/26/2022 Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $12.05 Cullinan Oncology, Inc. ( NASDAQ:CGEM ‚Ai Get Rating )‚Aos share price gapped up before the market opened on Thursday . The stock had previously closed at $12.05, but opened at $12.40. Cullinan Oncology shares last traded ... the company in a report on Friday, March 18th. Finally, SVB Leerink reaffirmed an ‚Auoutperform‚Au rating on shares of Cullinan Oncology in a report on Tuesday, February 8th.The company‚Aos 50-day simple ...
3/18/2022 HC Wainwright Cuts Cullinan Oncology (NASDAQ:CGEM) Price Target to $53.00 - Watch List News Cullinan Oncology ( NASDAQ:CGEM ‚Ai Get Rating ) had its price objective lowered by analysts at HC Wainwright from $55.00 to $53.00 in a report released on Friday, Benzinga reports. The firm presently has a ‚Aubuy ... Auhold‚Au rating in a report on Thursday, February 10th. SVB Leerink reissued an ‚Auoutperform‚Au rating on shares of Cullinan Oncology in a report on Tuesday, February 8th.Get Cullinan Oncology alerts: Shares of ...
3/15/2022 Early Breast Cancer Treatment Lynparza Now Has FDA Approval ... PARP inhibitor and the first targeted therapy for the post-surgery breast cancer context known as adjuvant treatment.As per SVB Leerink analyst Andrew Berens, M.D., the ajudvant breast cancer setting could represent a $1.5 ... data during the plenary at the American Society of Clinical Oncology conference last year.A new analysis has revealed that patient survival has improved in a ‚Austatistically significant and clinically meaningful‚Au way. According to ...
3/9/2022 Gossamer Bio (NASDAQ:GOSS) Upgraded to ‚ÄúHold‚Äù at Zacks Investment Research ... clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company‚Aos product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology ... the company in a research note on Monday, January 10th. SVB Leerink raised their price target on Gossamer Bio from $15.00 to $16.00 and gave the stock an outperform rating in a research note on ...
3/8/2022 AVEO Pharmaceuticals (NASDAQ:AVEO) Lifted to Hold at StockNews.com ... a hold rating in a report issued on Friday.Several other equities research analysts have also commented on the company. SVB Leerink restated a buy rating and set a $18.00 price target on shares of ... biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded ...
3/2/2022 Q2 2022 Earnings Estimate for Kura Oncology, Inc. (NASDAQ:KURA) Issued By SVB Leerink Kura Oncology, Inc. (NASDAQ:KURA ‚Ai Get Rating ) ‚Ai Stock analysts at SVB Leerink issued their Q2 2022 earnings per share (EPS) estimates for Kura Oncology in a report issued on Thursday, February 24th. SVB Leerink analyst J. Chang forecasts that the company will post earnings of ($0.54) per share for the quarter. SVB Leerink currently has a ‚AuOutperform‚Au rating and a $28.00 target price on the stock. SVB ...
3/1/2022 Guardant Health (NASDAQ:GH) Lowered to Sell at Zacks Investment Research Daily Political ... a research note issued to investors on Monday morning, Zacks.com reports. According to Zacks, ‚AuGuardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data ... equities research analysts have also recently commented on the company. SVB Leerink cut their price target on Guardant Health from $170.00 to $140.00 and set an outperform rating for the company in a report on ...
2/27/2022 Kura Oncology (NASDAQ:KURA) Price Target Increased to $27.00 by Analysts at Credit Suisse Group - Stock Observer Kura Oncology (NASDAQ:KURA ‚Ai Get Rating ) had its price objective lifted by Credit Suisse Group from $25.00 to $27.00 in a research report issued to clients and investors on Friday, PriceTargets.com reports. The firm ... Au rating in a report on Wednesday, February 16th. Finally, SVB Leerink cut their price target on Kura Oncology from $41.00 to $28.00 and set an ‚Auoutperform‚Au rating for the company in a report ...
2/27/2022 Kura Oncology (NASDAQ:KURA) Shares Gap Down After Analyst Downgrade Kura Oncology, Inc. (NASDAQ:KURA ‚Ai Get Rating ) shares gapped down before the market opened on Friday after SVB Leerink lowered their price target on the stock from $41.00 to $28.00. The stock had previously closed at $14.59, but opened at $13.93. SVB Leerink currently has an outperform rating on the stock. Kura Oncology shares last traded at $14.94, with a volume of 4,604 shares changing hands.Several other equities ...
2/26/2022 Kura Oncology (NASDAQ:KURA) Price Target Lowered to $28.00 at SVB Leerink Kura Oncology (NASDAQ:KURA ‚Ai Get Rating ) had its price target cut by SVB Leerink from $41.00 to $28.00 in a research note released on Friday, Price Targets.com reports. They currently have an outperform rating on the stock. SVB Leerink also issued estimates for Kura Oncology‚Aos Q2 2022 earnings at ($0.54) EPS and FY2023 earnings at ($2.42) EPS.A number of other research firms also recently commented on KURA ...
2/25/2022 Kura Oncology (NASDAQ:KURA) Shares Gap Down on Analyst Downgrade - American Banking News American Banking News Shares of Kura Oncology, Inc. (NASDAQ:KURA ‚Ai Get Rating ) gapped down before the market opened on Friday after SVB Leerink lowered their price target on the stock from $41.00 to $28.00. The stock had previously closed at $14.59, but opened at $13.93. SVB Leerink currently has an outperform rating on the stock. Kura Oncology shares last traded at $14.94, with a volume of 4,604 shares trading hands.KURA has ...
2/21/2022 Turning Point Therapeutics Inc. (TPTX): Does this stock hold the most enticing factor today? ... oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Guggenheim Healthcare Talks 2022 Oncology Day on February 9 and the 11th Annual SVB Leerink Global Healthcare Conference on February 16. You can read further details hereTurning Point Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1 ...
2/19/2022 Mereo BioPharma Group (NASDAQ:MREO) Given Outperform Rating at SVB Leerink The Markets Daily SVB Leerink reaffirmed their outperform rating on shares of Mereo BioPharma Group (NASDAQ:MREO) in a research report released on Thursday, Zacks.com reports.Separately, Needham & Company LLC reaffirmed a buy rating and issued a $10.00 ... and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS ...
2/9/2022 BioXcel Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference BioXcel Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceNEW HAVEN, Conn., Feb. 09, 2022 (GLOBE NEWSWIRE) ‚Ai BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will present at the upcoming SVB Leerink 11th Annual Global Healthcare Conference on Wednesday ...
1/12/2022 Bolt Biotherapeutics (NASDAQ:BOLT) Upgraded by Zacks Investment Research to ‚ÄúBuy‚Äù ... oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company‚Aos principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California. ‚AuA number of other research analysts also recently commented on the company. SVB Leerink reaffirmed a buy rating on shares of Bolt Biotherapeutics in a report on Thursday, December 9th. Morgan Stanley downgraded Bolt Biotherapeutics from an overweight rating ...